Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C.001 in Retinal Pigment Epithelium Mediated Maculopathy
NCT07594236Phase 1Recruiting
- Sponsor
- Cellio Therapeutics
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial in maculopathy, geographic atrophy (GA), Stargardt disease (STGD) and 1 more (3 arms), sponsored by Cellio Therapeutics. Primary endpoint: Incidence of Ocular and Systemic Adverse Events at 3 months. Started Apr 2026; status: recruiting.
02
Conditions
maculopathygeographic atrophy (GA)Stargardt disease (STGD)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT07594236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594236.